|
1
|
Cazzola M: Introduction to a review
series: The 2016 revision of the WHO classification of tumors of
hematopoietic and lymphoid tissues. Blood. 127:2361–2364. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lagunas-Rangel FA: A new history: The 2016
revision of the WHO classification of tumors of hematopoietic and
lymphoid tissues. Austin Leuk. 1:10012016.
|
|
3
|
Lukenbill J and Hill B:
Relapsed/Refractory diffuse large B-cell lymphoma: Review of the
management of transplant-eligible patients. Leuk Lymphoma.
56:293–300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jain P, Fayad LE, Rosenwald A, Young KH
and O'Brien S: Recent advances in de novo CD5+ diffuse
large B cell lymphoma. Am J Hematol. 88:798–802. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reagan PM and Davies A: Current treatment
of double hit and double expressor lymphoma. Hematology Am Soc
Hematol Educ Program. 2017:295–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saumyaranjan M, Arun P, Moien L, Ansh G,
Parashant R, Minakshi S, Ajay G, Ranjit S and Atul S:
Clinicopathological profile of primary double expressor lymphoma.
Clin Lymphoma Myeloma Leuk. 19 (Suppl 1):S2572019. View Article : Google Scholar
|
|
7
|
Choe JY, Park M, Yun JY, Na HY, Go H, Kim
HJ, Oh S and Kim JE: PELI1 expression is correlated with MYC and
BCL6 expression and associated with poor prognosis in diffuse large
B-cell lymphoma. Mod Pathol. 29:1313–1323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smith SM: Aggressive B-cell lymphoma: The
double-hit and double-expressor phenotypes. Clin Adv Hematol Oncol.
15:40–42. 2017.PubMed/NCBI
|
|
9
|
Danilova OV, Dumont LJ, Levy NB, Lansigan
F, Kinlaw WB, Danilov AV and Kaur P: FASN and CD36 predict survival
in rituximab-treated diffuse large B-cell lymphoma. J Hematop.
6:11–18. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Menendez JA and Lupu R: Fatty acid
synthase (FASN) as a therapeutic target in breast cancer. Expert
OpinTher Targets. 21:1001–1016. 2017. View Article : Google Scholar
|
|
11
|
Wang H, Xi Q and Wu G: Fatty acid synthase
regulates invasion and metastasis of colorectal cancer via wnt
signaling pathway. Cancer Med. 5:1599–1606. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Menendez JA and Lupu R: Fatty acid
synthase and the lipogenic phenotype in cancer pathogenesis. Nat
Rev Cancer. 7:763–777. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y
and Huang SH: Fatty acid synthase expression in osteosarcoma and
its correlation with pulmonary metastasis. Oncol Lett. 4:878–882.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun TH, Zhong X, Song HH, Liu JM, Li JG,
Leung F, Lu WW and Liu ZL: Anoikis resistant mediated by FASN
promoted growth and metastasis of osteosarcoma. Cell Death Dis.
10:2982019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu N, Li Y, Zhao Y, Wang Q, You Jc, Zhang
Xd and Ye Lh: A novel positive feedback loop involving
FASN/p-ERK1/2/5-LOX/LTB4/FASN sustains high growth of breast cancer
cells. Acta Pharmacol Sin. 32:921–929. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bian Y, Yu Y, Wang S and Li L:
Up-regulation of fatty acid synthase induced by EGFR/ERK activation
promotes tumor growth in pancreatic cancer. Biochem Biophys Res
Commun. 463:612–617. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Akiyama T, Choong PF and Dass CR: RANK-Fc
inhibits malignancy via inhibiting ERK activation and evoking
caspase-3-mediated anoikis in human osteosarcoma cells. Clin Exp
Metastasis. 27:207–215. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kapadia B, Nanaji NM, Bhalla K, Bhandary
B, Lapidus R, Beheshti A, Evens AM and Gartenhaus RB: Fatty acid
synthase induced S6Kinase facilitates USP11-eIF4B complex formation
for sustained oncogenic translation in DLBCL. Nat Commun.
9:8292018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed
SO, Ajarim D, Al-Dayel F, Bavi P and Al-Kuraya KS: Inhibition of
fatty acid synthase suppresses c-met receptor kinase and induces
apoptosis in diffuse large B-cell lymphoma. Mol Cancer Ther.
9:1244–1255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gonzalez-Guerrico A and Lupu R: Fatty acid
synthase (FASN) as a therapeutic target for breast cancer
metastasis. Cancer Res. 69 (Suppl 24):61602009.
|
|
21
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E and Lister TA: Recommendations for
initial evaluation, staging, and response assessment of hodgkin and
non-hodgkin lymphoma: The lugano classification. J Clin Oncol.
32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Conformation of molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Johnson NA, Slack GW, Savage KJ, Connors
JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, et
al: Concurrent expression of MYC and BCL2 in diffuse large B-cell
lymphoma treated with rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone. J Clin Oncol. 30:3452–3459. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bogusz AM, Kovach AE, Le LP, Feng D,
Baxter RH and Sohani AR: Diffuse large B-cell lymphoma with
concurrent high MYC and BCL2 expression shows evidence of active
B-cell receptor signaling by quantitative immunofluorescence. PLoS
One. 12:e01723642017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Giró-Perafita A, Sarrats A, Pérez-Bueno F,
Oliveras G, Buxó M, Brunet J, Viñas G and Miquel TP: Fatty acid
synthase expression and its association with
clinico-histopathological features in triple-negative breast
cancer. Oncotarget. 8:74391–74405. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Puig T, Blancafort A, Casoliva G, Oliveras
G, Casas M, Buxo M, Saiz E, Viñas G, Dorca J and Porta R:
Prospective analysis of fatty acid synthase (FASN) in breast cancer
tissue of early-stage breast cancer patients. Cancer Res. 72 (24
Suppl):P4-09-10. 2012.PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta DeltaC(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yao S, Xu F, Chen Y, Ge Y, Zhang F, Huang
H, Li L, Lin D, Luo X, Xu J, et al: Fbw7 regulates apoptosis in
activated B-cell like diffuse large B-cell lymphoma by targeting
Stat3 for ubiquitylation and degradation. J Exp Clin Cancer Res.
36:102017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tarantelli C, Gaudio E, Kwee I, Cascione
L, Bernasconi E, Hillmann P, Stathis A, Stussi G, Fabbro D, Wicki
A, et al: The dual PI3K/mTOR inhibitor PQR309 has synergistic
activity with other targeted agents in diffuse large B cell
lymphomas. Blood. 126:40052015. View Article : Google Scholar
|
|
30
|
Takahashi H, Miura K, Nakagawa M, Sugitani
M, Amano Y, Kurita D, Sakagami M, Ohtake S, Uchino Y, Kodaira H, et
al: Negative impact of concurrent overexpression of MYC and BCL2 in
patients with advanced diffuse large B-cell lymphoma treated with
dose-intensified immunochemotherapy. Leuk Lymphoma. 57:2784–2790.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li L, Zhang X, Zhang T, Song Z, Hu G, Li
W, Li L, Qiu L, Qian Z, Zhou S, et al: Prognostic significance of
BCL-2 and BCL-6 expression in MYC-positive DLBCL. Clin Lymphoma
Myeloma Leuk. 18:e381–e389. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma Z, Niu J, Cao Y, Pang X, Cui W, Zhang W
and Li X: Clinical significance of ‘double-hit’ and
‘double-expression’ lymphomas. J Clin Pathol. 73:126–138. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Johnston PB, LaPlant B, McPhail E,
Habermann TM, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS,
Ansell SM and Witzig TE: Everolimus combined with R-CHOP-21 for
new, untreated, diffuse large B-cell lymphoma (NCCTG 1085
[Alliance]): Safety and efficacy results of a phase 1 and
feasibility trial. Lancet Haematol. 3:e309–e316. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chiappella A, Witzig TE, Vitolo U,
Gascoyne R, Russo J, Amoroso B, Hudak K, Ogunkanmi A, Xu Y, Ruiz W,
et al: ROBUST: Phase III randomized study of LENALIDOMIDE/R-CHOP VS
PLACEBO/R-chop in untreated ABC-type diffuse large B-cell lymphoma
and feasibility of cell of origin subtyping. Hematol Oncol. 35:419.
2017. View
Article : Google Scholar
|
|
35
|
Brower V: Ibrutinib promising in subtype
of DLBCL. Lancet Oncol. 16:e4282015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Westin JR, Nastoupil L, Hagemeister F,
Fayad L, Young K, McDonnell T, Chuang H, Ahmed S, Nair R, Steiner
R, et al: SMART start: Rituximab, lenalidomide, and ibrutinib alone
prior to combination with chemotherapy for patients with newly
diagnosed diffuse large B-cell lymphoma. Hematol Oncol. 37:78–79.
2019. View Article : Google Scholar
|
|
37
|
Gelebart P, Zak Z, Anand M, Belch A and
Lai R: Blockade of fatty acid synthase triggers significant
apoptosis in mantle cell lymphoma. PLoS One. 7:e337382012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kant S, Kumar A and Singh SM: Myelopoietic
efficacy of orlistat in murine hosts bearing T cell lymphoma:
Implication in macrophage differentiation and activation. PLoS One.
8:e823962013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Long QQ, Yi Yx, Qiu J, Xu CJ and Huang PL:
Fatty acid synthase (FASN) levels in serum of colorectal cancer
patients: Correlation with clinical outcomes. Tumour Biol.
35:3855–3859. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ezzeddini R, Taghikhani M, Somi MH, Samadi
N and Rasaee MJ: Clinical importance of FASN in relation to HIF-1α
and SREBP-1c in gastric adenocarcinoma. Life Sci. 224:169–176.
2019. View Article : Google Scholar : PubMed/NCBI
|
